Case report: Treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches

F1000Res. 2019 Nov 26:8:2002. doi: 10.12688/f1000research.21216.2. eCollection 2019.

Abstract

Hidradenitis suppurativa and psoriasis are considered chronic inflammatory diseases suggesting the existence of common pathogenetic pathways. We present two cases of comorbid psoriasis and hidradenitis suppurativa, treated with certolizumab pegol and brodalumab due to failure of response to other conventional therapies. Monoclonal antibody therapies have revolutionized the treatment of chronic inflammatory disorders such as psoriasis and hidradenitis suppurativa. Given the good clinical response to anti-IL-17 and anti-tumor necrosis factor agents in patients undergoing psoriasis and hidradenitis treatment, investigations on this direction could represent the starting point in new therapeutic approach for revolutionary treatment in these difficult-to-treat diseases.

Keywords: brodalumab; certolizumab; hidradenitis suppurativa; psoriasis.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Certolizumab Pegol / therapeutic use
  • Female
  • Hidradenitis Suppurativa* / complications
  • Hidradenitis Suppurativa* / drug therapy
  • Humans
  • Male
  • Psoriasis* / complications
  • Psoriasis* / drug therapy
  • Quality of Life
  • Skin

Substances

  • Antibodies, Monoclonal, Humanized
  • brodalumab
  • Certolizumab Pegol

Grants and funding

The author(s) declared that no grants were involved in supporting this work.